Nkarta, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Nkarta, Inc. (NKTX) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $31.82 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-08-10
- 2026-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $31.82M.
- 2026-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $33.59M.
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $35.40M.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $37.08M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-06-30 | $31.82M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $33.59M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $35.40M 10-K · filed 2026-03-25 |
| 2025-09-30 | $37.08M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $38.93M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $40.83M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $42.79M 10-K · filed 2025-03-26 |
| 2024-09-30 | $45.90M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $49.01M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $50.03M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $52.13M 10-K · filed 2024-03-21 |
| 2023-09-30 | $54.27M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $56.44M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $58.64M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $60.81M 10-K · filed 2023-03-16 |
| 2022-09-30 | $60.05M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $45.68M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $46.11M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $4.26M 10-K · filed 2022-03-17 |
| 2021-09-30 | $4.53M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $4.79M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $5.01M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $4.03M 10-K · filed 2021-03-25 |
| 2020-09-30 | $4.25M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $4.47M 10-Q · filed 2020-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |